Antitumor Effects of Juncus effusus L. subsp. effusus in a Mammary Tumor Model: Regulation of ERα, p53, PCNA, and HIF-1α
Molecules, cilt.31, sa.15, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 15
- Basım Tarihi: 2026
- Doi Numarası: 10.3390/molecules31152581
- Dergi Adı: Molecules
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: estrogens, flavonoids, mammary tumor, medical plants, oncoproteins
- Gazi Üniversitesi Adresli: Evet
Özet
Estrogen receptor-positive breast cancer remains difficult to treat, driving the search for new therapeutic agents. Juncus effusus L., a medicinal plant rich in bioactive constituents, has shown preliminary anticancer activity, yet its efficacy in hormone-responsive tumor models in vivo has not been established. We evaluated the antitumor effects of the ethyl acetate sub-extract of J. effusus L. subsp. effusus in an N-methyl-N-nitrosourea (NMU)-induced rat mammary tumor model, assessing tumor burden, histopathology, and molecular markers. Thirty-six Sprague–Dawley rats were divided into six groups (n = 6): sham, control, reference, and three groups receiving the sub-extract at 100, 200, or 400 mg/kg. After NMU induction (50 mg/kg), treatment began once tumor volumes reached approximately 2000 mm3 and continued for eight weeks. The 200 mg/kg dose markedly reduced tumor volume relative to control (p < 0.0001) and lowered both ERα and PCNA expression (p < 0.001 and p < 0.0001). The 100 and 200 mg/kg groups also showed lower p53 and ERα mRNA levels than the other treatment groups. HIF-1α, though elevated in control tumors, declined only modestly and without statistical significance after treatment. These results indicate that J. effusus subsp. effusus, particularly at 200 mg/kg, suppresses proliferation and modulates ERα- and p53 expression, supporting its potential for further preclinical investigation.